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Abstract
Tauopathies are a class of neurodegenerative diseases associated with the pathological 
aggregationof the tau protein in the human brain. The best known of these illnesses is Alzheimer's 
disease (AD); a disease where the microtubule associated protein tau (MAPT) becomes 
hyperphosphorylated (lowering its binding affinity to microtubules) and aggregates within neurons 
in the form of neurofibrillary tangles (NFTs). In this paper we examine whether environmental 
factors play a significant role in tau pathogenesis. Our studies were conducted in a double mutant 
mouse model that expressed the human tau gene and lacked the gene for murine tau. The human 
tau mouse model was tested for the transgene's ability to respond to an environmental toxicant. 
Pups were developmentally exposed to lead (Pb) from postnatal day (PND) 1-20 with 0.2% Pb 
acetate. Mice were then sacrificed at PND 20, 30, 40 and 60. Protein and mRNA levels for tau and 
CDK5 as well as tau phosphorylation at Ser396 were determined. In addition, the potential role of 
miRNA in tau expression was investigated by measuring levels of miR-34c, a miRNA that targets 
the mRNA for human tau, at PND20 and 50. The expression of the human tau transgene was 
altered by developmental exposure to Pb. This exposure also altered the expression of miR-34c. 
Our findings are the first of their kind to test the responsiveness of the human tau gene to an 
environmental toxicant and to examine an epigenetic mechanism that may be involved in the 
regulation of this gene's expression.
*Corresponding author at: Interdisciplinary Neurosciences, University of Rhode Island, Kingston, RI, United States. 
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1. Introduction
Tauopathies are a class of neurodegenerative diseases associated with the pathological 
aggregation of the tau protein in the human brain. There are approximately thirty known 
tauopathies, with different clinical, pathological and biological characteristics (Caillet-
Boudin et al., 2015). Some tauopathies are considered familial and are related to precise 
mutations of the tau gene, while others are sporadic in nature with no direct genetic links. 
Perhaps the best-known tauopathy is Alzheimer's disease (AD), the most common form of 
dementia affecting elderly people over the age of 65 and the sixth leading cause of death in 
the United States (Alzheimer's, 2015). A key pathological feature of AD is the aggregation 
of the tau protein and its deposition within neurons in the form of neurofibrillary tangles 
(NFTs). In the healthy brain, tau stabilizes microtubules and supports intracellular 
transportation. If tau is hyperphosphorylated, its binding affinity for tubulin is lowered, 
increasing the probability that tau will aggregate and form tangles. The aberrant 
phosphorylation of tau compromises microtubule stability, axonal transport and, therefore, 
cognitive function (Gendron and Petrucelli, 2009).
Patients that develop AD prior to age 65 are considered to have Early Onset AD and may 
exhibit hereditable mutations in the Amyloid Precursor Protein (APP), Presenilin1 (PSEN1) 
or Presenilin2 (PSEN2) genes (Liddell et al., 2001). Most individuals that develop AD 
(>95%) have sporadic or Late Onset AD (LOAD) (Bekris et al., 2010). Genome analyses 
have failed to identify a clear genetic etiology for this form of AD, suggesting the possibility 
that environmental exposures and related epigenetic modifications play an important role in 
the pathogenesis of sporadic forms of AD and other tauopathies (Karch and Goate, 2014; 
Lunnon and Mill, 2013; Rosenthal and Kamboh, 2014).
The environment contains a number of toxicants that are risk factors for the development of 
neurodegenerative diseases. These include, but are not limited to, pesticides (such as DDT), 
metals, and air pollution (Dosunmu et al., 2007). The heavy metal lead (Pb) still poses a 
danger as an environmental toxicant. While extant research does not provide clear evidence 
that Pb exposure is the cause of AD or other tauopathies, the identification of relationships 
between Pb poisoning and cognitive decline began to surface after several longitudinal and 
cross-sectional studies were performed on the elderly. The Normative Aging Study, a 
prospective continuing study started by the Veterans Administration in 1963, has shown that 
participants with higher levels of Pb in the blood/bone exhibited diminished performance in 
cognitive measures such as the Wechsler Adult Intelligence Scale-Revised and Mini-Mental 
state examination (Payton et al.,1998; Weisskopf et al., 2007, 2004; Wright et al., 2003).
In conjunction with this data collected in humans, recent research has demonstrated that 
mice exposed to Pb postnatally performed worse during cognitive behavior tests as aged 
adults (Bihaqi and Zawia, 2013). These behavioral deficits correlated with the changes in the 
protein and gene expression levels of tau, phosphorylated tau, related enzymes and 
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transcription factors (Bihaqi et al., 2014; Bihaqi and Zawia, 2013). More recently we 
discovered that epigenetic mediators such as microRNA may paly a role in mediating these 
changes in gene expression (Masoud et al., 2016). Developmental Pb studies completed in 
the wild-type mice were replicated in non-human primates. Results from the primate study 
were consistent with those found in the mouse model. Furthermore, the exposed primates 
showed a development of NFTs at the end of life, a classic pathological marker of AD 
(Bihaqi and Zawia, 2013).
To translate the results seen in our rodent and primate studies into a human application, we 
have implemented the use of a transgenic mouse model that possesses the gene for human 
tau. Prior studies have provided strong evidence for the ability of an environmental toxin to 
affect the murine tau gene, but there is a critical need to examine the relationship between 
toxins and the human tau gene because the mouse and human genes produce different 
protein products. The mouse gene does not produce all of the isoforms produced by the 
human gene. This whole line of investigation would have to come to a dead end if it was 
discovered that the human gene was not sensitive to the effects of Pb exposure.
The present study utilizes a transgenic mouse that has a homozygous knock-out of the 
murine tau gene and is hemizygous for the human tau gene. On a molecular level, this 
transgene includes the promoter, intronic regions, and regulatory regions of the human 
MAPT gene. The transgenic mouse model develops all six isoforms of the human protein 
tau, including both 3R and 4R isoforms. Since the adult mouse brain contains exclusively 
the 4R tau isoform, while the adult human brain contains roughly equal amounts of 3R and 
4R, this model has a representative human tau ratio (Andorfer et al., 2003).
The primary purpose of the current research was to explore the utility of this transgenic 
mouse model in the study of interactions between environmental toxicants and the human 
tau gene. Our investigation examined whether the human tau transgene is responsive to 
exposure to a developmental toxicant by determining the effect of this exposure on tau 
protein and gene expression. In addition, we surveyed the impact of the toxicant on a 
population of miRNA that target the mRNA for MAPT.
2. Methodology
2.1. Animals and exposure
This study employed the transgenic mouse model B6.Cg-Mapttm1(GFP)Klt 
Tg(MAPT)8cPdav/J [Jackson Laboratory Stock 005491, Bar Harbor, ME]). No endogenous 
mouse MAPT is detected in these mice, but all six isoforms (including both 3R and 4R 
forms) of human MAPT are expressed. Mice were bred in the Animal Care Facility at the 
University of Rhode Island (Kingston, RI). All experiments were performed in accordance 
with the standard guidelines and protocol approved by the University of Rhode Island 
Institutional Animal Care and Use Committee (IACUC) with supervision of the university's 
veterinarian.
The transgenic mice were divided into two groups. One group of mice was exposed to Pb 
during the first 20 days of postnatal life according to the protocol we have published 
Dash et al. Page 3
Neurotoxicology. Author manuscript; available in PMC 2017 December 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
previously (Bihaqi et al., 2014). Mice in the second cohort were not exposed to Pb and 
served as controls. The first group was exposed to 0.2% Pb Acetate via the drinking water of 
their respective dams. Lead acetate (500 mg) was dissolved in 250 mL of deionized water. 
This exposure protocol causes the concentration of Pb in the cerebellum of PND 20 rodents 
(0.25+/- 0.07 μg/g) to be approximately three times the level seen in control animals (Zawia 
and Harry, 1996). Blood levels have been shown to be 46.43 (μg/dl during Pb exposure but 
are reduced to basal levels in adults (Basha et al., 2005). Exposure began 24 h after birth 
(PND 1) and continued until weaning (PND 20). Mice were euthanized with CO2 at PND 
20, PND 30, PND 40 and PND 60 for protein and mRNA measures and at PND 20 and PN 
D50 for miRNA assays. For each time point and exposure group there was an n = 3. The 
brains were removed and placed on ice followed by immediate storage at −80°C.
2.2. Genotyping
Pups born in-house were weaned, separated by sex, and genotyped at PND 20. Tail snips of 
2 mm were taken from each mouse and a DNA extraction was performed on each sample. 
The resulting DNA was amplified with the following primers— transgene sense: 5′-
CGAAGTGATGGAAGATCACG-3′ and transgene antisense: 5′-
GTCTTGGTGCATGGTGTAGC-3′. Amplification was conducted under the following 
conditions: 94 °C for 2min followed by 30 cycles of 94 °C for 30 s, 55 °C for 30 s and 72 °C 
for 1 min. The amplified product was electrophoresed on a 2% agarose gel at 100 V for 90 
min and imaged on the Amersham Typhoon Imager Scanner FLA 9000 (GE Life Sciences, 
Piscataway, NJ).
2.3. Protein levels
Western blots were utilized to examine protein levels of total tau, phosphorylated tau 
Ser396, and cyclin dependent kinase 5 (CDK5). The following protocol was used to prepare 
samples for total tau, Ser396, and CDK5: 50 mg of cerebral cortical brain tissue was 
homogenized in 1 mL of radioimmunoprecipitation assay (RIPA) lysis buffer containing 10 
mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1 
mM ethylenediaminetetraacetic acid and 2 μL protease inhibitor, and 10 μL phosphatase 
inhibitor. The homogenates were placed on ice for 10min before being centrifuged at 8000× 
RPM for 10 min at 4°C. Lysate protein concentrations were determined by a bicinchoninic 
acid assay (Thermo Scientific Pierce, Rockford, IL), at 560 nm using the Spectra-Max 
Multimode plate reader (Molecular Devices, Sunnyvale, CA). Following protein 
standardization, samples were prepared for western blotting according to the concentrations 
listed in Table 1.
Samples were separated on polyacrylamide gels at 85 V for 90min and then transferred to 
PVDF membranes (Millipore, Billerica, MA). Membranes were blocked at room 
temperature and incubated overnight with blocking buffer and primary antibody (Table 1) 
with gentle shaking at 4°C. The membranes were then washed with TBST three times and 
incubated with the appropriate secondary antibody. The membranes were washed 3 times 
with TBST and 3 times with TBS. Membranes were imaged on the Odyssey® Infrared 
Imaging System (Li-Cor, Lincoln, NE). All blots were normalized to housekeeping proteins 
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GAPDH or β-Actin. Total tau and phospho-tau blots were normalized to GAPDH. CDK5 
was normalized to β-Actin.
2.4. Immunohistochemistry
Immunohistochemistry was used to visually confirm the presence of hyperphosphorylated 
tau in 13-month-old mice. While our study involved developmental profiles, we used older 
mice to confirm the presence of tau immunoreactvity and to observe for pathological 
deposits associated with the presence of the human tau gene. These normally do not fully 
manifest until an older age. According to a protocol previously published (Subaiea et al., 
2015), mice were deeply anesthetized with an intraperitoneal injection of 0.1 ml/10 g of 
xylazine-ketamine mixture (100-10 mg/ml) and were perfused transcardially with 100 ml of 
perfusion wash containing 0.8% sodium chloride, 0.8% sucrose, 0.4% dextrose, 0.034% 
anhydrous sodium cacodylate, and 0.023% calcium chloride. Mice were then perfused with 
100 mL of perfusion fix containing 4% paraformaldehyde, 4% sucrose, and 1.07% 
anhydrous sodium cacodylate, and their brains were removed. The extracted brains were 
post-fixed in the perfusion fix solution overnight and then cryopreserved in 30% sucrose 
solution at −20 °C. Fixed brains were sent to NeuroScience Associates (Knoxville, TN) and 
stained with 1:2500 phospho-tau Thr181 (Thermo Scientific Pierce, Rockford, IL).
2.5. RNA and micro RNA (miRNA) isolation and real-time PCR
Total RNA was isolated from Pb-exposed and non-exposed cerebral cortex tissue according 
to the TRIzol method (Invitrogen, Carlsbad, CA). Purity and concentration were confirmed 
using a Nanodrop UV/vis Spectrophotometer (Thermo Scientific, Wilmington, DE). First 
strand complementary DNA (cDNA) was synthesized from 1 (μg total RNA using the iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA) for mRNA and NCode™ VILO™ miRNA 
cDNA Synthesis Kit (Invitrogen, CA) for miRNA. cDNA was amplified using real-time 
polymerase chain reaction (PCR). The SYBR Green quantitative real-time PCR assay was 
performed in 12.5 μl (20 μl for miRNA) reactions using 1 μl cDNA template, 1 X SYBR 
Green master mix (Applied Biosystems, Foster City, CA), 0.5 μM forward and reverse 
primers, and deionized H2O. The primers utilized can be found in Table 2. Amplification 
was performed on ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City, CA) 
following the standard protocol: 50°C for 2min followed by 95 °C for 10min, then 40 cycles 
of 95 °C for 15 s and 60 °C for 1 min. Results were analyzed with with ViiA 7, and 
expression was reported relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA with the 2−ΔΔCT method for mRNA and 2−ΔCT for miRNA which was normalized to 
small nucleolar RNA 202 (sno202).
2.6. Statistical analysis
Western blot bands were quantified using the Li-Cor Odyssey infrared image system. Real 
time PCR curves were quantified using Viia7 Real-Time PCR System software. All 
measurements were made in triplicate and all values are presented as mean istandard error of 
the mean. Analyzing the protein and mRNA levels of the Pb-exposed group versus the 
control groups tested the responsiveness of the transgene to Pb exposure. One-way analysis 
of variance (ANOVA) for each gene was performed with the Newman-Keuls multiple-
comparison post hoc test. Newman-Keuls was chosen as the preferred method for a stepwise 
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approach to pairwise comparisons of the mean responses due to increased power among 
smaller number of treatment groups. To determine the significance of interaction between 
Pb-exposure and the time points investigated, a two-way ANOVA and a Newman-Keuls 
multiple-comparison post hoc test was performed for each gene's protein expression. Effect 
sizes were calculated to assess the magnitude of the interaction between Pb-exposure and 
time. The level of significance for each ANOVA was set at α= 0.05. All analyses were 
performed using Sigma Stat 3.5 computer software.
3. Results
3.1. Genotyping and immunohistochemical characterization of the human tau phenotype
Genotyping and immunohistochemistry were conducted on aged sibilings of the 
experimental cohorts as part of the model validation. Analysis of DNA obtained from the 
tails of PND20 mice revealed clear differences between mice carrying the transgene versus 
non-carrier controls. Immunohistochemical staining for phosphorylated tau (Thr181) in 
older (13 month) transgene carriers demonstrated clear evidence of hyperphosphorylation in 
multiple cerebral cortical regions, including the internal capsule (Supplementary Fig. 1A) 
and the external capsule (Supplementary Fig. 1B).
3.2. Effect of Pb exposure on biomarkers of neurodegeneration
Protein levels of cerebral cortical total tau normalized to GAPDH were analyzed by Western 
blot after postnatal dosing with 0.2% Pb acetate for 20days (Fig. 1A). One-way ANOVA 
revealed a dramatic increase in total tau protein levels in the brains of Pb-exposed mice at 
PND 20 and 30 which then returned to basal levels by PND 40-60 (p=0.008, p=0.006 
respectively) (Fig. 1B). A two-way ANOVA revealed a statistically significant interaction 
between the time points and Pb-exposure (p=<0.001). The interaction effect, η2, for this 
relationship is 0.512 revealing that 51 % of the variance was due to an interaction between 
time and exposure. Tau mRNA was evaluated for Pb's ability to affect expression. Analysis 
of tau mRNA levels shows that at PND 20, postnatal Pb exposure has a similar up-regulation 
effect on the expression of tau at the transcriptional level (Fig. 1C).
The cerebral cortical levels of phosphorylated tau Ser396 normalized to GAPDH were 
analyzed by Western blot after postnatal lead exposure (Fig. 2A). Results from a one-way 
ANOVA revealed a significant increase of phosphorylated protein expression in Pb-exposed 
mice at PND 20 and PND30, which also normalized at PND40-60 (p=0.001 and p=0.001, 
respectively) (Fig. 2B). Two-way ANOVA findings revealed a statistically significant 
interaction between the time points and exposure (p < 0.001). The h2 for this interaction is 
0.510 revealing that 51% of the variance is attributed to the interaction between exposure 
and time.
Cerebral cortical CDK5 normalized to β-actin was analyzed by Western blot to measure the 
effect of Pb on the kinase's protein expression levels (Fig. 3A). CDK5 levels in Pb-exposed 
mice showed an up-regulation trend at every time point as compared to controls (Fig. 3B). 
At PND 40 and PND 60, a one-way ANOVA test reported a significant difference (p = 0.001 
and p< 0.001, respectively). A two-way ANOVA revealed that the effect of Pb exposure does 
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not depend on the time point. Stated differently, there is no statistically significant 
interaction between the time points and exposure (p = 0.067). η2 for this interaction is 0.127; 
a finding that reveals just under 13% of the variance can be attributed to the interaction 
effect between Pb exposure and time. CDK5 mRNA levels also followed a pattern of 
consistent upregulation in the Pb-exposed mice compared to unexposed controls (Fig. 3C). 
One-way ANOVA results revealed no statistical significance between the treatment groups 
for CDK5 gene expression.
Recent studies by us have suggested that microRNAs may play a role in mediating Pb-
induced changes in gene expression. We have shown previously that exposing wild-type 
mice to Pb produces a transient increase in the expression of miRNA that target APP mRNA 
and the mRNA for proteins involved in promoter methylation (Masoud et al., 2016). This 
increase in the expression of select miRNA coincided with a period of decreased protein 
expression that followed the Pb exposure, suggesting that the miRNA might be inhibiting the 
translation of these proteins. In the present study, we found that Pb exposure produced an 
analogous and significant (p=0.037) increase in the expression of miR-34c between PND20 
and PND50 (Fig. 4). This miRNA has been shown to target the mRNA for human MAPT 
(Wu et al., 2013).
4. Discussion
Extant findings for wild-type mice have provided evidence that developmental Pb exposure 
has an effect on tau, its kinase's and phospho-tau (Bihaqi et al., 2014). The expressed 
hypothesis of this study was focused on identifying the responsiveness of the human tau 
transgene to an environmental exposure. Initial genotyping confirmed that transgenic mice 
adequately express human tau and that murine endogenous tau was expectedly absent due to 
its deletion. Immunohistochemical staining in aged mice with an antibody for phospho-tau 
site Thr181 validates that the mouse model has high levels of phosphorylated tau in various 
brain structures as they age. This is in accordance with previously published findings 
(Andorfer et al., 2003).
Western blotting and quantitative real time PCR demonstrated that Pb has an effect on the 
human tau gene transcription and translation. Previous studies have shown postnatal 
exposure in wild-type mice increases levels of tau, phosphorylated tau, and its related 
enzymes (Bihaqi et al., 2014). We tested to see the same pattern within the transgenic mouse 
model between PND 20-60. The findings from this current study illustrated that Pb indeed 
has an effect on the human tau gene which occurs within a stage-specific developmental 
window and then normalized by adulthood. These observations are consistent with 
numerous studies reported by our group on the impact of developmental Pb exposure and 
gene expression and more recently shown to occur for tau (Bihaqi et al., 2014). The latent 
effects of elevated tau levels in late life seen in the wild-type mice are possibly being 
established and further aging of these mice would be expected to reveal a delayed 
upregulation in this biomarker in old age.
The phosphorylated tau serine 396 protein levels follow the same upregulation pattern of the 
total tau protein levels (Figs.1–2). This infers that as more total tau is being translated, 
Dash et al. Page 7
Neurotoxicology. Author manuscript; available in PMC 2017 December 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
phosphorylation of the protein is also increasing; suggesting that the hyperphosphorylation 
of tau is substrate driven. The total tau mRNA levels illustrate that the upregulation of 
transcription at PND 20 results in excessive protein translation and subsequent 
phosphorylation at PND 20 and 30. At PND 40 and PND 60 the transcriptional levels are 
similar in pattern to the protein levels.
Additional western blotting showed consistent elevated levels of CDK5 in Pb-exposed mice 
compared to controls. This was analogous to the two-year Pb exposure study done in the 
wild-type mouse model (Bihaqi et al., 2014); however, it is important to note that both 
CDK5 levels and gene expression are belatedly elevated on PND 40 and such elevation is 
sustained throughout their adulthood. This suggests that while CDK5 can contribute to the 
posttranslational modification of tau, it is not responsive to substrate levels and may be 
activated by alternate pathways. It is also important to note that Ser396 is a major target of 
glycogen synthase kinase 3 (GSK3), a second kinase of tau (Kimura et al., 2014). CDK5 
was the primary kinase evaluated in this study because of its importance in abnormal tau 
phosphorylation as well as many GSK3 sites, including Ser396, needing to be primed by 
CDK5 initially (Kimura et al., 2014).
MicroRNAs (miRNA) are small non-coding RNA of ∼22 nucleotides that act as important 
post-transcriptional regulators of gene expression by binding to the 3′ un-translated regions 
of their target mRNAs, resulting in mRNA degradation or the inhibition of protein 
translation (Goodall et al., 2013). It has been shown that miR-34c binds to human MAPT 
mRNA and thus inhibits the expression of MAPT protein (Wu et al., 2013). In the present 
study we demonstrate that early postnatal Pb exposure causes an increase in the expression 
of this miRNA that coincides with the post-exposure normalization of tau expression that we 
describe above. This data suggests that miRNA, including miR-34c, may play a critical role 
in “correcting” the transient Pb-induced over-expression of tau, similar to the role suggested 
for miRNA in the normalization of protein expression in wild-type mice exposed to Pb 
(Masoud et al., 2016).
In summary, these studies demonstrate for the first time that exposure to an environmental 
toxin can modulate a human gene and biomarkers associated with AD and tauopathies. 
When compared with our previous work using wild-type animals, the present results indicate 
that the human tau gene may in fact be more sensitive than the murine tau gene to 
developmental Pb exposure. Future studies will explore the combined effects of the 
environment and susceptible genes across the lifespan through old age. Furthermore, 
epigenetic pathways that maybe associated with this genetic reprogramming will be 
examined.
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Fig. 1. 
Total tau expression in mice with postnatal exposure to Pb. (A) Changes in the 
developmental profiles of tau protein expression in the cerebral cortex of control and 
developmental exposure group (Pb). (B) Quantification of protein expression by 
normalization to GAPDH. (C) Quantification of mRNA levels of total tau normalized to 
GAPDH. Each data point in the bar diagram represents the mean ± SEMs (n = 3) for protein 
and gene expression. **p < 0.010 as compared to unexposed controls. *p < 0.05 as 
compared to unexposed controls and independently verified. Total tau protein and gene 
expression was altered by postnatal Pb exposure.
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Fig. 2. 
Phospho-tau Ser396 expression in mice with postnatal exposure to Pb. (A) Changes in the 
developmental profiles of phosphor-tau Ser396 protein expression in the cerebral cortex of 
control and developmental exposure group (Pb). (B) Quantification of protein expression by 
normalization to GAPDH. Each data point in the bar diagram represents the mean±SEMs (n 
= 3) for protein expression. ***p < 0.001 as compared to unexposed controls. Phopho-tau 
Ser936 protein expression was altered by postnatal Pb exposure.
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Fig. 3. 
CDK5 expression in mice with postnatal exposure to Pb. (A) Changes in the developmental 
profiles of CDK5 protein expression in the cerebral cortex of control and developmental 
exposure group (Pb). (B) Quantification of protein expression by normalization to β-actin. 
(C) Quantification of mRNA levels of CDK5 normalized to β-actin. Each data point in the 
bar diagram represents the mean ± SEMs (n = 3) for protein and gene expression. ***p < 
0.001 as compared to unexposed controls. CDK5 protein and gene expression was altered by 
postnatal Pb exposure.
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Fig. 4. 
Expression of miR-34c relative to sno202 in control animals (dotted line) and 
Pbexposedanimals (PbE, solid line) at PND 20 and PND 50. Results expressed as mean ± 
SEMs (n = 3 with measurements in triplicates). *p<0.05 as compared to unexposed controls.
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Table 2
Primer Sequences for qPCR.
Target FORWARD PRIMER REVERSE PRIMER
Tau 5′ -TGA ACC AGG ATG GCT GAG C-3′ 5′-TTG TCA TCG CTT CCA GTC C-3′
CDK5 5′ -GGC TAA AAA CCG GGA AAC TC-3′ 5′-CCA TTG CAG CTG TCG AAA TA-3′
SP1 5′ -TCA TAC CAG GTG CAA ACC AA-3′ 5′-AGG TGA TGT TCC CAT TCA GG-3′
GAPDH 5′ -AGG TCG GTG TGA ACG GAT TTG-3′ 5′-TGT AGA CCA TGT AGT TGA GGT CA-3′
miR-34c [miRBase ID: MI0000403]: 5′-AGGCAGTGTAGTTAGCTGATTGC-3′ Universal primer provided with the kit
Sno202 5′ -GCTGTACTGACTTGATGAAG-3′ 5′-CATCAGATGGAAAAGGGTTC-3′
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